Your session is about to expire
← Back to Search
Stereotactic Radiotherapy for Lung Cancer
Study Summary
This trial looks at a new way to treat lung tumours using high doses of radiation over a shorter period of time. It will study how safe and effective it is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 1 & 2 trial • 160 Patients • NCT02052648Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are individuals being enrolled in the study currently?
"Affirmative. According to the information posted on clinicaltrials.gov, this research project is still enrolling patients as of October 21st 2022; it was initially published on March 1 2006 and requires 200 participants from a single medical centre."
Has the FDA sanctioned Stereotactic Radiation as a viable therapy?
"We predict that stereotactic radiation's safety is a 2 on the scale of 1 to 3 because clinical trials have revealed reassuring data, but efficacy has yet been confirmed."
How many participants are being observed in the current research project?
"Affirmative. Accurate information is available on clinicaltrials.gov and shows this medical trial was initially posted in March of 2006, with the latest update made on October 21st 2022. This study aims to recruit 200 individuals from a single location."
Share this study with friends
Copy Link
Messenger